Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $49,950.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock in a transaction that occurred on Friday, March 22nd. The shares were purchased at an average cost of $19.98 per share, with a total value of $49,950.00. Following the purchase, the chief executive officer now owns 5,347,777 shares of the company’s stock, valued at approximately $106,848,584.46. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Wednesday, March 20th, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $17.68 per share, with a total value of $26,520.00.
• On Monday, March 4th, Snehal Patel acquired 4,100 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $13.03 per share, with a total value of $53,423.00.
• On Thursday, February 15th, Snehal Patel acquired 12,700 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $11.07 per share, with a total value of $140,589.00.

Greenwich LifeSciences Price Performance

GLSI stock opened at $19.94 on Friday. Greenwich LifeSciences, Inc. has a one year low of $7.58 and a one year high of $21.44. The firm has a 50 day simple moving average of $12.93 and a two-hundred day simple moving average of $10.92.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of GLSI. Vanguard Group Inc. grew its stake in Greenwich LifeSciences by 150.2% in the 1st quarter. Vanguard Group Inc. now owns 375,200 shares of the company’s stock worth $7,362,000 after buying an additional 225,213 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Greenwich LifeSciences in the 2nd quarter worth approximately $891,000. Millennium Management LLC purchased a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at $765,000. Susquehanna International Group LLP purchased a new stake in shares of Greenwich LifeSciences in the 1st quarter valued at $512,000. Finally, Occudo Quantitative Strategies LP purchased a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at $199,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of Greenwich LifeSciences in a research note on Wednesday, February 28th.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.